Which HBA 1cand lipid targets in patients with type 2 diabetes?;Quelles cibles glycémiques et lipidiques viser chez un patient diabétique de type 2?

Revue Medicale de Liege

Volumn 67, Issue 2, 2012, Pages 98-103

  Paquot, N ^a,b   Scheen, A J ^a,b  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Cardiovascular risk; Dyslipidaemia; Guidelines; HbA 1c; Hypoglycaemia; LDL; Non HDL; Statin; Therapeutic target; Type 2 diabetes

Indexed keywords

HEMOGLOBIN A1C; LOW DENSITY LIPOPROTEIN CHOLESTEROL; GLYCOSYLATED HEMOGLOBIN; LIPID;

ARTICLE; BLOOD GLUCOSE MONITORING; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; DIABETIC PATIENT; HUMAN; HYPOGLYCEMIA; ISCHEMIC HEART DISEASE; LIPOPROTEIN BLOOD LEVEL; NON INSULIN DEPENDENT DIABETES MELLITUS; BLOOD; CARDIOVASCULAR DISEASE; CASE REPORT; DIABETIC ANGIOPATHY; DRUG DELIVERY SYSTEM; DRUG EFFECT; DYSLIPIDEMIA; GLUCOSE BLOOD LEVEL; MALE; METABOLISM; MIDDLE AGED; PRACTICE GUIDELINE; RISK FACTOR;

BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DRUG DELIVERY SYSTEMS; DYSLIPIDEMIAS; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; LIPIDS; MALE; MIDDLE AGED; PRACTICE GUIDELINES AS TOPIC; RISK FACTORS;

EID: 84857433568     PISSN: 00353663     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Rydén L, Standl E, Bartnik M, et al.- Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The task force on diabetes and cardiovascular diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J, 2007, 28, 88-136. (Pubitemid 46137814)
2. Scheen AJ, Van Gaal LF.- Le diabète de type 2 au coeur du syndrome métabolique : plaidoyer pour une prise en charge globale. Rev Med Liège, 2005, 60, 566-571. (Pubitemid 40941544)
3. Paquot N, Scheen AJ.- Prévention cardio-vasculaire chez le patient diabétique de type 2. Rev Med Liège, 2003, 58, 271-274. (Pubitemid 36841132)
4. Scheen AJ, Paquot N.- Quelle nouvelle donne pour traiter les patients diabétiques de type 2 ? Médecine des Maladies métaboliques, 2009, 3, 141-146.
5. Scheen AJ, Paquot N.- Approche multirisque du patient diabétique de type 2: désaccord sur les valeurs cibles suite à l'étude ACCORD. Rev Med Suisse, 2010, 6, 1582-1587.
6. Rutter MK, Nesto RW.- Blood pressure, lipids and glucose in type 2 diabetes: how low should we go? Re-discovering personalized care. Eur Heart J, 2011, 32, 2247-2255.
7. Krzesinski J-M, Scheen AJ.- Quelles cibles tensionnelles viser chez un patient diabétique de type 2 ? Rev Med Liège, 2012, 67, 51-56.
8. American Diabetes Association.- Standards of medical care in diabetes - 2012. Diabetes Care, 2012, 35 (Suppl 1), S11-63.
9. Gaede P, Lund-Andersen H, Parving HH, Pedersen O.- Effect of a multifactorial intervention on mortality in type 2 diabetes patients. N Engl J Med, 2008, 358, 580-591. (Pubitemid 351214285)
10. Hemingsen B, Lund SS, Gluud C, et al.- Intensive glycaemic control for patients with type 2 diabetes: systematic review with meta-analysis and trial sequential analysis of randomised clinical trials. BMJ, 2011, 343, d6898.
11. Turnbull FM, Abraira C, Anderson RJ, et al.- Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia, 2009, 52, 2288-2298.
12. Radermecker R, Philips JC, Jandrain B, et al.- Contrôle glycémique et morbi-mortalité cardio-vasculaire chez le patient diabétique de type 2. Résultats des études ACCORD, ADVANCE et VA-Diabetes. Rev Med Liège, 2008, 63, 511-518.
13. Miller ME, Bonds DE, Gerstein HC.- The effects of baseline characteristics, glycaemia treatment approach, and glycated haemoglobin concentration on the risk of severe hypoglycaemia : post hoc epidemiological analysis of the ACCORD study. BMJ, 2010, 340, b5444. doi: 10.1136/bmj.b5444.
14. Riddle MC, Ambrosius WT, Brillon DJ, et al.- Epidemiologic relationships between A1C and all-cause mortality during a median 3.4-year follow-up of glycemic treatment in the ACCORD trial. Diabetes Care, 2010, 33, 983-990.
15. Pozzilli P, Leslie RD, Chan J, et al.- The A1C and ABCD of glycaemia management in type 2 diabetes : a physician's personalized approach. Diabetes Metab Res Rev, 2010, 26, 239-244.
16. Nathan DM, Buse JB, Davidson MB, et al.- Medical management of hyperglycaemia in type 2 diabetes : a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia, 2009, 52, 17-30.
17. Scheen AJ, Radermecker RP, De Flines J, Ducobu J.- Actualités thérapeutiques en lipidologie. Rev Med Liège, 2007, 62, 324-328.
18. Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS), Catapano AL, Reiner Z, De Backer G, et al.- ESC/EAS Guidelines for the management of dyslipidaemias : the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis, 2011, 217 (Suppl 1), S1-44.
19. Descamps OS, De Backer G, Muls E, Scheen AJ, Belgian Atherosclerosis Society/ Belgian Lipid Club.- Les nouvelles recommandations européennes pour le traitement des dyslipidémies en prévention cardio-vasculaire. Rev Med Liège, 2012, 67, sous presse.
20. Scheen AJ, Radermecker RP.- Ezétimibe (Ezetrol®) chez le patient diabétique. Rev Med Liège, 2009, 64, 606-611.
21. Scheen AJ, Luyckx FH, Lefèbvre PJ.- Comment j'explore... le syndrome métabolique par sa nouvelle définition dite de "consensus". Rev Med Liège, 2006, 61, 48-52. (Pubitemid 43211764)
22. Ducobu J, Scheen A, Van Gaal L, et al.- Belgian expert opinion : how to reduce the residual risk in atherogenic dyslipidaemic patients: place of fibrates. Acta Cardiol, 2008, 63, 235-248. (Pubitemid 351548712)
23. ACCORD Study Group.- Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med, 2010, 362, 1563-1574.
24. Scheen AJ, Van Gaal LF.- ACCORD-LIPID et ACCORD-EYE: vers un nouveau positionnement du fénofibrate chez le patient diabétique de type 2. Rev Med Liège, 2010, 65, 533-539.
25. Scheen AJ.- Inertie thérapeutique dans la pratique médicale : causes, conséquences, solutions. Rev Med Liège, 2010, 65, 232-238.
26. Paquot N.- Effets néfastes du défaut d'observance hygiéno-diététique et médicamenteuse chez le patient diabétique. Rev Med Liège, 2010, 65, 326-331.
27. Scheen AJ.- Patient coronarien avec co-morbidités: intégrer indications et contre-indications dans le raisonnement pharmaco- thérapeutique. Rev Med Liège, 2010, 65, 476-481.